GeoVax Labs Inc. To Discuss Zika Vaccine Development Progress At American Society For Virology Meeting

ATLANTA, GA--(Marketwired - June 13, 2016) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company specializing in developing human vaccines, announced today that its Chief Scientific Officer, Dr. Harriet Robinson, will give an oral presentation at the American Society for Virology's 35th Annual Meeting, to be held at Virginia Polytechnic Institute and State University in Blacksburg, Virginia on June 18-22, 2016.

Dr. Robinson's presentation, entitled "Development of a Zika Vaccine," will be delivered at 2:00pm on Tuesday, June 21, 2016 during the late-breaking Zika workshop at the conference. Further details from Dr. Robinson's talk will be released immediately following her presentation.

About GeoVax
GeoVax Labs, Inc., is a clinical-stage biotechnology company developing human vaccines against infectious diseases using its MVA-VLP vaccine platform. The Company's development programs are focused on vaccines against Zika Virus, HIV, and hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa). GeoVax also recently began programs to evaluate the use of its MVA-VLP platform in cancer immunotherapy and in developing a vaccine to treat chronic Hepatitis B infections. GeoVax's vaccine platform supports in vivo production of non-infectious VLPs from the cells of the individual receiving the vaccine. The production of VLPs in the person being vaccinated mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection.